Tirzepatide produces meaningfully greater weight loss — roughly 47% more in the first direct head-to-head trial. But semaglutide works well for most people, costs significantly less, and is the smarter starting point for anyone prioritizing value or just beginning GLP-1 therapy.
The right choice depends on your goals, budget, and medical history — not just which drug performs better in trials.
What are these medications?
Both semaglutide and tirzepatide belong to a class of medications called GLP-1 receptor agonists. They work by mimicking hormones your gut naturally releases after eating — hormones that tell your brain you're full, slow the rate at which your stomach empties, and help regulate blood sugar.
The result: significantly reduced appetite, fewer cravings, and meaningful weight loss when combined with healthy habits. Both require a prescription from a licensed provider and are typically injected subcutaneously once a week.
The brand names you've probably heard
| Active ingredient | For weight loss | For type 2 diabetes |
|---|---|---|
| Semaglutide | Wegovy (2.4mg) | Ozempic (up to 2.0mg) |
| Tirzepatide | Zepbound (up to 15mg) | Mounjaro (up to 15mg) |
Wegovy and Ozempic are the same molecule (semaglutide) made by the same company (Novo Nordisk) — just different doses and FDA approvals. The same applies to Zepbound and Mounjaro (tirzepatide, made by Eli Lilly). Most people accessing these through telehealth will be using compounded versions of either molecule, which contain the same active ingredient at a significantly lower price.
How they differ mechanically
This is where tirzepatide separates itself. Semaglutide activates one receptor — the GLP-1 receptor. Tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
The GIP receptor plays a distinct role in fat metabolism. GIP receptors in fat cells regulate how lipids are stored and released. When activated alongside GLP-1 receptors, the combination appears to produce synergistic effects on fat mobilization and energy expenditure — which helps explain why tirzepatide consistently produces greater weight loss in clinical data.
Think of semaglutide as a single-key system that unlocks appetite suppression. Tirzepatide uses two keys simultaneously — it unlocks the same door, plus an adjacent one that affects how your body handles fat storage. Both open doors that matter. Tirzepatide opens more of them.
What the clinical data actually shows
Until May 2025, comparing these medications required looking across separate trials conducted in different populations — which creates meaningful uncertainty. The SURMOUNT-5 trial, published in the New England Journal of Medicine, was the first randomized head-to-head comparison between the two drugs in a single population.
The trial enrolled 751 adults with obesity but without type 2 diabetes. Participants were randomly assigned to the maximum tolerated dose of either tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg), given weekly for 72 weeks.
Tirzepatide also outperformed semaglutide across every secondary endpoint — including waist circumference reduction (−18.4 cm vs −13.0 cm) and the percentage of participants achieving weight loss thresholds of 10%, 15%, 20%, and 25%.
On the 25% weight loss threshold specifically: 31.6% of tirzepatide participants achieved this vs 16.1% on semaglutide. That's a meaningful gap for anyone pursuing significant weight loss.
What this means in practical terms
For a 200-pound person, the difference in average outcomes is roughly 33 lbs lost on semaglutide vs 40 lbs on tirzepatide. That's meaningful — but important context: semaglutide still produces what would have been considered a remarkable result before this class of medications existed.
Both drugs also produced significant improvements in cardiometabolic risk factors including blood pressure, blood sugar, and lipid levels. These health benefits extend well beyond weight alone.
Side effects: what to expect
Both medications share a similar side effect profile because they work through overlapping mechanisms. Gastrointestinal effects are the most common — and they're most pronounced during dose escalation in the first few months.
| Side effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | ~44% (STEP-1 trial) | ~40% (SURMOUNT-1) |
| Diarrhea | Common during titration | Similar rate |
| Constipation | Less common | Slightly more common |
| Fatigue | Early weeks | Similar |
| Injection site reaction | Mild, uncommon | Mild, uncommon |
Neither medication should be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both carry an FDA boxed warning about thyroid C-cell tumors observed in animal studies. Your provider will screen for these before prescribing.
The practical takeaway: neither medication is meaningfully "gentler" on the stomach than the other. Side effects are manageable for most people and improve significantly after the first 4–8 weeks at a stable dose. Starting at a low dose and titrating slowly is the most effective way to minimize early discomfort.
Cost in 2026: what you'll actually pay
Brand-name pricing for both medications without insurance is prohibitive for most people. The real story in 2026 is compounded versions accessed through telehealth — which contain the same active ingredient at dramatically lower cost.
Compounded semaglutide remains the most affordable entry point — often 70–85% cheaper than brand-name. Compounded tirzepatide is also available through telehealth but typically costs more than compounded semaglutide, though less than brand-name Zepbound.
Compounded semaglutide and tirzepatide use the same active molecule as brand-name versions, prepared by licensed 503A or 503B compounding pharmacies. They are not FDA-approved finished products, but the active pharmaceutical ingredient must meet USP standards. Quality depends heavily on the pharmacy — choosing a reputable telehealth provider that uses licensed, tested compounding pharmacies matters significantly.
Which is right for you?
The honest answer: tirzepatide produces more weight loss on average. But "more" doesn't automatically mean "better for you specifically." Here's a practical framework for thinking through the choice.
Your situation → suggested starting point
How to access either medication in 2026
Both medications require a prescription from a licensed healthcare provider. The most accessible route for most people in 2026 is through a telehealth platform — an online medical visit, a review of your health history, and if appropriate, a prescription sent to a compounding pharmacy that ships directly to your door.
Our full comparison of GLP-1 telehealth programs — including cost, medical oversight quality, pharmacy transparency, and what each program includes — is in our guide to the best GLP-1 programs without insurance.
Licensed US providers reviewing your case — not automated approvals.
Transparent pricing that includes medication, consultations, and supplies — not "starting at" prices that grow with hidden fees.
503A or 503B licensed pharmacy — ask specifically. This is the primary quality differentiator in compounded medications.
Ongoing provider access for dose adjustments and side effect management. Telehealth-only platforms vary significantly in how much support they provide after the initial prescription.
The bottom line
Tirzepatide is the more powerful medication by the numbers. The SURMOUNT-5 trial published in the New England Journal of Medicine — the first direct head-to-head comparison — showed tirzepatide producing roughly 47% more weight loss than semaglutide over 72 weeks.
But semaglutide remains a clinically meaningful, highly effective option that produces significant weight loss for most people, costs less, and has a longer track record of real-world use. For anyone starting GLP-1 therapy or working with a limited budget, semaglutide is a sensible and well-supported first choice.
The decision isn't really about which drug is "better" in the abstract — it's about which one is right for your specific health situation, budget, and goals. That conversation belongs with a licensed provider who can evaluate your individual case.
Our independently researched guide to GLP-1 telehealth programs covers the top providers for both semaglutide and tirzepatide — including pricing, what's included, and what to watch out for.
See our GLP-1 program comparisonMedical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications require evaluation and prescription by a licensed healthcare provider. Always consult a qualified physician before starting any new medication. Individual results vary. If you are experiencing a medical emergency, contact emergency services immediately.